血清PlGF与PAPP-A在早孕期筛查早产型子痫前期中的比较:校正阿司匹林治疗效果后
两项独立前瞻性研究共25 226例单胎孕妇,在11+0至13+6周筛查中比较血清PlGF与PAPP-A联合母体危险因素、MAP和UtA-PI对早产型子痫前期的预测效能,并校正阿司匹林治疗效果。结果显示PlGF可提高检出率,而PAPP-A未显著改善任何生物标志物组合的检出率。
要点
- 在母体危险因素基础上加入PlGF,10%筛查阳性率下早产型子痫前期检出率提高18.4%。
- 联合母体因素和MAP时加入PlGF,检出率提高19.9%;再加UtA-PI时提高7.0%。
- PAPP-A未显著改善任何生物标志物组合的早产型子痫前期检出率。
核心结论
- 早孕期PlGF对早产型子痫前期的预测效能优于PAPP-A。
研究设计与样本
- 非干预性多中心子痫前期筛查研究,纳入两项独立前瞻性单胎妊娠研究,分别有8775例和16 451例孕妇在11+0至13+6周常规评估。
主要发现
- 合计25 226例孕妇中,678例(2.7%)发生子痫前期,194例(0.8%)为早产型子痫前期。
- 在10%筛查阳性率下,母体危险因素筛查中加入PlGF使早产型子痫前期检出率提高18.4%(95%CI 12.2-24.6)。
- 母体因素联合MAP筛查中加入PlGF使检出率提高19.9%(95%CI 13.6-26.2);母体因素联合MAP和UtA-PI筛查中加入PlGF使检出率提高7.0%(95%CI 2.3-11.6)。
- PAPP-A未显著改善任何生物标志物组合的检出率。
关键数值与推荐
- 采用竞争风险模型估算基于母体危险因素及联合MAP、UtA-PI和PlGF或PAPP-A的个体化37周前分娩子痫前期风险。
- 采用McNemar检验比较使用PlGF与PAPP-A筛查的早产型子痫前期检出率,并校正阿司匹林效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the predictive performance for preterm-pre-eclampsia (PE) in first-trimester screening by serum placental growth factor (PlGF) versus pregnancy associated plasma protein-A (PAPP-A), in combination with maternal risk factors, mean arterial pressure (MAP) and uterine artery pulsatility index (UtA-PI), after adjustment for the effect of aspirin in women receiving this treatment. DESIGN: Non-intervention multicentre screening studies for PE in singleton pregnancies. SETTING: Maternity hospitals. POPULATION: Two independent prospective studies of 8775 and 16 451 women with singleton pregnancies attending for routine assessment at 11+0 -13+6 weeks' gestation. METHODS: The competing risks model was used to estimate patient-specific risks of delivery with PE at <37 weeks' gestation based on maternal risk factors and combinations with MAP, UtA-PI and either PlGF or PAPP-A. McNemar's test was used to compare the detection rate (DR) of preterm-PE of screening utilising PlGF versus PAPP-A, after adjustments for the effects of aspirin. MAIN OUTCOME MEASURE: Predictive performance for preterm-PE. RESULTS: In the combined data of 25 226 women, including 678 (2.7%) who developed PE, there were 194(0.8%) with preterm-PE. Addition of PlGF improved the DR of preterm-PE, at 10% screen positive rate, by 18.4% (95% CI 12.2-24.6) in screening by maternal risk factors, by 19.9% (95% CI 13.6-26.2) in screening by maternal factors and MAP, and by 7.0% (95% CI 2.3-11.6) in screening by maternal factors, MAP and UtA-PI. PAPP-A did not significantly improve the DR provided by any combination of biomarkers. CONCLUSION: The predictive performance of first trimester PlGF for preterm-PE is superior to that of PAPP-A.
引用
- Wright D, Tan MY, O'Gorman N, et al. Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment. BJOG. 2022. PMID: 35015330. doi:10.1111/1471-0528.17096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。